
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is currently valued at $58 per share using a risk-adjusted sum-of-the-parts methodology that examines the clinical, regulatory, and commercial potential of each indication and assigns a probability of success. With a well-capitalized balance sheet and promising drug candidates in its pipeline, such as zanidatamab and pasritamig, Zymeworks has the potential for significant growth in the biopharmaceutical industry. Additionally, RPRX's financing deal and share repurchase plan also bode well for the company's future financial stability and potential value to investors.
Bears say
Zymeworks is a clinical-stage biopharmaceutical company that faces financial and commercial risks due to its reliance on clinical trials for its pipeline, regulatory approval for its drugs, and potential competition in its markets. These risks, along with a complex valuation methodology, suggest a negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares